PENICILLIN V BENZATHINE TETRAHYDRATE

First approved in 1955

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H20N2.2C16H18N2O5S.4H2O
Molecular Weight	1013.184
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PENICILLIN V BENZATHINE TETRAHYDRATE

Structure Search

SMILES

O.O.O.O.C(CNCC1=CC=CC=C1)NCC2=CC=CC=C2.CC3(C)S[C@@H]4[C@H](NC(=O)COC5=CC=CC=C5)C(=O)N4[C@H]3C(O)=O.CC6(C)S[C@@H]7[C@H](NC(=O)COC8=CC=CC=C8)C(=O)N7[C@H]6C(O)=O

InChI

InChIKey=WGLORUYLLMHSJU-CJHXQPGBSA-N

InChI=1S/2C16H18N2O5S.C16H20N2.4H2O/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;;;;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);1-10,17-18H,11-14H2;4*1H2/t2*11-,12+,14-;;;;;/m11...../s1

HIDE SMILES / InChI

Molecular Formula	C16H18N2O5S
Molecular Weight	350.39
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H20N2
Molecular Weight	240.3434
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00417
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf

Penicillin V is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Penicillin V has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Penicillin V results from the inhibition of cell wall synthesis and is mediated through Penicillin V binding to penicillin binding proteins (PBPs). Penicillin V is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor. Used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Staphylococcus aureus 70 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16495241	Inhibitor 8504
Penicillin-binding protein 1A 45 Target ID: Q8XJ01 Gene ID: 990276.0 Gene Symbol: pbpA Target Organism: Clostridium perfringens (strain 13 / Type A) Sources: http://www.drugbank.ca/drugs/DB00417	Inhibitor 8504
Penicillin-binding protein 2a 17 Target ID: CHEMBL3512 Sources: http://www.drugbank.ca/drugs/DB00417	Inhibitor 8504
Streptococcus pneumoniae 25 Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3172134	Inhibitor 8504
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: http://www.genome.jp/dbget-bin/www_bget?D05411+D00497+D08360	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Pneumococcal infections 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Curative	Approved 8583	Penicillin V Approved Use Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date 1990
Streptococcal infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Curative	Approved 8583	Penicillin V Approved Use Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date 1990
Staphylococcal infections 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Curative	Approved 8583	Penicillin V Approved Use Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date 1990

C_max

Value	Dose	Analyte	Population
6.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
35.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
6.89 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
19.01 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.36 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.94 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	unknown, oral		PENICILLIN V POTASSIUM serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9006528	unhealthy, 1-12 Health Status: unhealthy Age Group: 1-12 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9006528	Disc. AE: Stomach cramps, Nausea... Other AEs: Diarrhea, Rash... AEs leading to discontinuation/dose reduction: Stomach cramps (0.46%) Nausea (0.46%) Other AEs: Diarrhea (0.8%) Rash (1.2%) Abdominal pain (0.8%) Infection (1.7%) Headache (1.2%) Vomiting (2.5%) Rhinitis (1.2%) Gastroenteritis (0.4%) Epistaxis (0.4%) Ear pain (2.1%) Cough increased (1.2%) Nausea (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/9006528
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1656738	unhealthy, 16+ Health Status: unhealthy Age Group: 16+ Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1656738	Disc. AE: Abdominal pain... AEs leading to discontinuation/dose reduction: Abdominal pain (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/1656738
590 mg 3 times / day multiple, oral Recommended Dose: 590 mg, 3 times / day Route: oral Route: multiple Dose: 590 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11815577	unhealthy, 28+/-7.9 Health Status: unhealthy Age Group: 28+/-7.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/11815577	Disc. AE: Nausea, Taste alteration... AEs leading to discontinuation/dose reduction: Nausea (grade 3, 0.88%) Taste alteration (grade 3, 0.88%) Sources: https://pubmed.ncbi.nlm.nih.gov/11815577
800 mg 4 times / day multiple, oral Highest studied dose Dose: 800 mg, 4 times / day Route: oral Route: multiple Dose: 800 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	unhealthy, 30.0 (6–73) Health Status: unhealthy Age Group: 30.0 (6–73) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	Sources: https://pubmed.ncbi.nlm.nih.gov/31585944
1 g 3 times / day multiple, oral Recommended Dose: 1 g, 3 times / day Route: oral Route: multiple Dose: 1 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	unhealthy, 31.0 (3–67) Health Status: unhealthy Age Group: 31.0 (3–67) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	Sources: https://pubmed.ncbi.nlm.nih.gov/31585944
3 g multiple, oral Recommended Dose: 3 g Route: oral Route: multiple Dose: 3 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1428189	unhealthy Health Status: unhealthy Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1428189	Disc. AE: Rash, Vomiting... AEs leading to discontinuation/dose reduction: Rash (0.57%) Vomiting (0.57%) Sources: https://pubmed.ncbi.nlm.nih.gov/1428189
500 mg 4 times / day multiple, oral Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Disc. AE: Hypersensitivity reaction, Diarrhea, Clostridium difficile... AEs leading to discontinuation/dose reduction: Hypersensitivity reaction (serious\|grade 5) Diarrhea, Clostridium difficile (mild\|grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-053377	http://www.3bsc.com/index/pro_info.php?id=91842
AHH Chemical co.,ltd	MT-57705	http://www.ahhchemical.com/product/MT-57705.html
Alfa Chemistry	AP87081	https://reagents.alfa-chemistry.com/product/penicillin-v-cas-87-08-1-17587.html
Aurora Fine Chemicals LLC	A17.930.778	http://online.aurorafinechemicals.com/info?ID=A17.930.778
Aurora Fine Chemicals LLC	K14.717.682	http://online.aurorafinechemicals.com/info?ID=K14.717.682
Avantor Inc	101095-750	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101095-750
BioSynth	W-109316	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/W-109316.html
BLD Pharm	BD290184	http://www.bldpharm.com/products/87-08-1.html
Glentham Life Sciences	GA2160	http://www.glentham.com/products/product/GA2160/
Hairui	HR140122	http://www.hairuichem.com/en/product/87-08-1.html
Lab Network	LN01343665	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343665
LGC Standards	DRE-A16045500AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16045500AL-100
LGC Standards	DRE-C16045500	https://www.lgcstandards.com/US/en/p/DRE-C16045500
MuseChem	R062176	https://www.musechem.com/product/R062176.html
Sigma-Aldrich	1504489_USP	https://www.sigmaaldrich.com/catalog/product/usp/1504489?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P1000000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/p1000000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S571986	https://www.smolecule.com/products/s571986
THE BioTek	bt-311879	https://www.thebiotek.com/product/others/bt-311879

PubMed

Title	Date	PubMed
Synthesis of novel hapten and production of generic monoclonal antibody for immunoassay of penicillins residues in milk.	2013	23452214
Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells.	2012-08-01	22609641
Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity.	2012-02	22112502
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.	2010-11	21139869
Prevalence of Group A b-Hemolytic Streptococcus Among Children with Tonsillopharyngitis in Kyrgyzstan: The Difficulty of Diagnostics and Therapy.	2010-10-13	21253454
How are antibacterials used in nursing homes? Results from a point-prevalence prescription study in 44 Norwegian nursing homes.	2010-10	20712026
Antibiotic prescribing practices by dentists: a review.	2010-07-21	20668712
Decreased Streptococcus pneumoniae susceptibility to oral antibiotics among children in rural Vietnam: a community study.	2010-03-31	20356399
A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis.	2010-03	20191044
Challenges of cellulitis in a lymphedematous extremity: a case report.	2009-12-22	20062550
[An exceptional component C3 deficiency revealed by serum protein electrophoresis].	2009-11-27	19939777
Antibiotic prescribing in paediatric populations: a comparison between Viareggio, Italy and Funen, Denmark.	2009-08	19349289
Hypersensitivity reactions to penicillins: studies in a group of patients with negative benzylpenicillin G skin test.	2009-06	19646073
Specific IgG antibodies in sera in patients with penicillin allergy.	2009-06	19067119
The role of phenoxymethylpenicillin, amoxicillin, metronidazole and clindamycin in the management of acute dentoalveolar abscesses--a review.	2009-04-11	19357666
SDRIFE (baboon syndrome) induced by penicillin.	2009-04	18699835
Acute tonsillopharyngitis in a family practice in Mostar, Bosnia and Herzegovina.	2009-03	19408639
Treatment of Lyme borreliosis.	2009	20067594
Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group A beta-Hemolytic Streptococcus pharyngitis in Children.	2009	20041005
Treatment and prevention of Lyme disease.	2009	19367098
Trends in number of consultations and antibiotic prescriptions for respiratory tract infections between 1999 and 2005 in primary healthcare in Kalmar County, Southern Sweden.	2009	19085427
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008-12	19337440
Drug use in children: cohort study in three European countries.	2008-11-24	19029175
A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya.	2008-11-18	19017387
Antistreptococcal treatment of guttate psoriasis: a controlled study.	2008-09	18937661
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.	2008-08	18505790
Antimicrobial susceptibility of periodontopathogenic bacteria.	2008-05	18326855
[Summary of the practice guideline 'Sore throat' (second revision) from the Dutch College of General Practitioners].	2008-02-23	18361191
Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers.	2007-12	18184536
Evaluation of phenoxymethylpenicillin treatment of acute otitis media in children aged 2-16.	2007-09	17846935
Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin.	2007-07	17510067
Leukocyte counts in urine reflect the risk of concomitant sepsis in bacteriuric infants: a retrospective cohort study.	2007-06-13	17567901
Dishing the dirt on asthma: What we can learn from poor hygiene.	2007-06	19707324
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.	2007-06	17446241
Meningomylocele: An update.	2007-04	19675798
Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients.	2007-03	17225142
[Express determination of beta-lactam antibiotics in biological matter with potentiometric sensors].	2007	20583465
[The microbiology of peritonsillar abscesses].	2007	18510073
Hypersensitivity to penicillin V with good tolerance to other beta-lactams.	2007	17323864
HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins.	2006-03-20	16584643
Clinical practice. Antibiotic allergy.	2006-02-09	16467547
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.	2006	22500153
Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin.	2006	16484823
Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V.	2005-12	16393332
Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy.	1990-11	1701026
Effect of drugs influencing synthesis of prostaglandins on haloperidol-induced catalepsy in rats.	1984-07-01	6440863
[Leukocytoclastic vasculitis due to drug allergy presenting as generalized pustular exanthema].	1981-09	6268571
Assessment of the "E' book as a tool for drug monitoring.	1981-03	6790651
[Immune hemolytic anemia and thrombocytopenia after peroral therapy with a penicillin derivative (phenoxymethylpenicillin)].	1977	415731
[The antiviral activity of the antibiotics beromycin and carminomycin].	1974-02	4219122

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bacterial Infection Mild to moderate infections: 125 to 500 mg orally every 6 to 8 hours

Route of Administration: Oral

In Vitro Use Guide

Penicillin V inhibited Staphylococcus aureus in human THP-1 macrophages (intracellular) with MIC90 of 0.015 mg/L

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:08:55 GMT 2025` Edited by `admin` on `Mon Mar 31 22:08:55 GMT 2025`
Record UNII	44MHH77OIC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENZATHINE PHENOXYMETHYLPENICILLIN TETRAHYDRATE

Preferred Name

English

PENICILLIN V BENZATHINE TETRAHYDRATE

Common Name

English

PHENOXYMETHYLPENICILLINE BENZATHINE TETRAHYDRATE

Common Name

English

HYDROUS PHENOXYMETHYLPENICILLIN BENZATHINE

Common Name

English

N<sup>1</sup>,N<sup>2</sup>-Dibenzylethane-1,2-diamine bis[(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate] tetrahydrate

Common Name

English

PHENOXYMETHYLPENICILLIN (BENZATHINE) TETRAHYDRATE [EP MONOGRAPH]

Common Name

English

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-, (2S,5R,6R)-, compd. with N1,N2-bis(phenylmethyl)-1,2-ethanediamine, hydrate (2:1:4)

Systematic Name

English

PHENOXYMETHYLPENICILLIN BENZATHINE [JAN]

Common Name

English

PHENOXYMETHYLPENICILLIN (BENZATHINE) TETRAHYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

44MHH77OIC